Castleark Management LLC Invests $574,000 in Repligen Co. (NASDAQ:RGEN)

Castleark Management LLC purchased a new position in Repligen Co. (NASDAQ:RGEN) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,120 shares of the biotechnology company’s stock, valued at approximately $574,000.

Other institutional investors also recently modified their holdings of the company. YHB Investment Advisors Inc. bought a new position in Repligen during the first quarter valued at about $26,000. Lazard Asset Management LLC lifted its holdings in shares of Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after buying an additional 136 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Repligen by 152.1% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after buying an additional 146 shares in the last quarter. Principal Securities Inc. purchased a new stake in shares of Repligen in the fourth quarter worth about $48,000. Finally, CWM LLC increased its position in shares of Repligen by 19.9% in the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 60 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of Repligen stock traded down $2.54 on Thursday, reaching $164.81. 396,015 shares of the stock were exchanged, compared to its average volume of 634,776. The company has a quick ratio of 5.24, a current ratio of 6.35 and a debt-to-equity ratio of 0.26. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13. The firm has a market capitalization of $9.21 billion, a price-to-earnings ratio of 661.16, a PEG ratio of 5.37 and a beta of 0.95. The business has a 50 day moving average price of $134.71 and a two-hundred day moving average price of $166.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The firm had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same period in the previous year, the business earned $0.53 earnings per share. The firm’s revenue for the quarter was down 3.2% on a year-over-year basis. Analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. UBS Group decreased their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and cut their target price for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th. Guggenheim initiated coverage on Repligen in a research note on Tuesday, June 18th. They issued a “neutral” rating for the company. Stephens reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research note on Tuesday. Finally, JPMorgan Chase & Co. raised their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $190.88.

Insider Activity

In related news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now owns 163,177 shares in the company, valued at approximately $27,456,162.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director Martin D. Madaus bought 1,615 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was purchased at an average cost of $124.94 per share, with a total value of $201,778.10. Following the transaction, the director now directly owns 4,613 shares in the company, valued at $576,348.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Anthony Hunt sold 20,072 shares of the stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.